MAIA Biotechnology terminates ATM equity offering agreement after raising ~$5.68M

MAIA Biotechnology, Inc.

Suspended sales and gave notice to terminate At The Market Offering Agreement with H.C. Wainwright, effective 7 business days after May 14, 2026.
Since March 28, 2025 prospectus supplement for $11.2M, sold 3,116,012 shares for gross proceeds of approx. $5,680,924.
No further sales under the ATM facility; termination will be effective upon expiration of the notice period.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MAIA Biotechnology, Inc. terminated At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-05-14).

Action: termination
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2026-05-14

Exact text from the filing

On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination will be effective 7-business days after May 14, 2026, in accordance with the terms of the sales agreement.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.